In a world-first trial, researchers at the Royal Adelaide Hospital (RAH) and the University of Adelaide are seeking participants to test a new slow-release ketamine tablet as an innovative option for treating depression. This Central Adelaide Local Health Network (CALHN) and University of Adelaide-led study aims to provide an alternative form of treatment for individuals who have not responded to other medications. Up to 55 percent of people with depression experience treatment-resistant depression, highlighting the need for new solutions.
Ketamine, commonly used for pain relief and anesthesia, acts on brain chemicals and can alter the brain’s interpretation of sensory stimuli. While ketamine is starting to be used as an alternative treatment for depression, its current administration methods can result in sporadic uptake, leading to unexpected side effects such as drowsiness, disorientation, and changes in blood pressure and heart rate. These side effects can discourage individuals from carrying out daily activities.
The slow-release ketamine tablet aims to address these challenges by gradually releasing the drug into the body, avoiding rapid highs and associated unpleasant symptoms. Initial volunteer trials have already been conducted, meeting safety requirements, and now the RAH is inviting individuals aged 18 and over who have not responded effectively to common antidepressant medications to participate in the trial.
In this groundbreaking study, participants will be closely monitored to assess the effectiveness and safety of the slow-release ketamine tablet. The researchers are hopeful that this innovative approach will provide a much-needed solution for individuals experiencing treatment-resistant depression. By focusing on gradual drug release, the study seeks to minimize unwanted side effects and improve the overall treatment experience.
This trial has the potential to revolutionize depression treatment by offering an alternative option for those who have not found relief through existing medications. By optimizing the drug’s delivery, the slow-release ketamine tablet may provide a more manageable and effective treatment option for individuals struggling with depression.
The researchers at the RAH and the University of Adelaide are committed to advancing mental health care and are excited about the potential impact of this innovative trial. Through continued research and collaboration, they aim to improve the lives of individuals with treatment-resistant depression and offer hope for a brighter future.
If you or someone you know has tried common antidepressant medications without success and is interested in participating in this groundbreaking trial, please reach out to the Royal Adelaide Hospital. Your participation could contribute to the development of new treatments and help countless individuals living with depression.
